J Pediatr Infect Dis 2022; 17(03): 163-169
DOI: 10.1055/s-0042-1748921
Original Article

COVID-19 Symptoms with Pre-Existing and Not Pre-Existing Neurological Disorders in Pediatrics

1   Department of Pediatric Neurology, Health Ministry Eskisehir City Hospital, Eskisehir, Turkey
,
2   Department of Pediatric Neurology, Health Ministry Bursa Yüksek İhtisas Eğitim Arastirma Hastanesi, Bursa, Turkey
› Author Affiliations
Funding None.

Abstract

Objective The symptoms of coronavirus disease 2019 (COVID-19) in children with pre-existing neurological disease are unknown. We aimed to find out the difference in the symptoms of children with pre-existing neurological disease and those without.

Methods In this single-center, retrospective, cohort study, 96 pediatric patients who had COVID-19 between March 2020 and April 2021 were enrolled.

Results There were 35 males and 61 females. The median age was 14 years (interquartile range [IQR] 10.25–16). Fever (38.5%), headache (35.4%), and cough (32.3%) were the most common symptoms. In 53.1%, neurological complaints (headache, taste-smell loss, vertigo, febrile seizure, coma, and ataxia), in 40.6%, respiratory symptoms (cough, dyspnea, rhinitis, and pharyngitis), and in 8.3%, gastrointestinal symptoms (gastroenteritis, vomiting, nausea, and abdominal pain) were seen. While 23 (62.2%) patients with fever did not have neurological complaints, 14 (37.8%) had neurological complaints (p = 0.017). Eight (21.6%) patients with fever were hospitalized (p = 0.067). Fever was seen significantly more frequently with pre-existing neurological disease (p < 0.001). Younger children were more likely to have fever (p = 0.008). Headaches and taste–smell loss were seen more frequently in patients with no pre-existing neurological disease (p < 0.001, p = 0.034, respectively). The patients with headaches were older than the ones without headaches (p < 0.001). Patients with headaches and loss of taste and smell were older than those without (p = 0.003).

Conclusion Neurological symptoms differed significantly between those who had pre-existing neurological disease and those who did not. Headaches and taste–smell loss were seen more frequently in patients with no pre-existing neurological disease. Fever was significantly higher in patients who had pre-existing neurological disease.

Note

The patient with encephalitis was reported as a case report elsewhere. The patient with ataxia was reported as a case report elsewhere.




Publication History

Received: 01 January 2022

Accepted: 29 March 2022

Article published online:
30 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 World Health Organization. World Health Organization coronavirus disease 2019 (COVID-19) situation report; 2020
  • 2 Kim Y, Walser SA, Asghar SJ, Jain R, Mainali G, Kumar A. A comprehensive review of neurologic manifestations of COVID-19 and management of pre-existing neurologic disorders in children. J Child Neurol 2021; 36 (04) 324-330
  • 3 Hasan A, Mehmood N, Fergie J. Coronavirus disease (COVID-19) and pediatric patients: a review of epidemiology, symptomatology, laboratory and imaging results to guide the development of a management algorithm. Cureus 2020; 12 (03) e7485
  • 4 She J, Liu L, Liu W. COVID-19 epidemic: disease characteristics in children. J Med Virol 2020; 92 (07) 747-754
  • 5 Ghodsi A, Azarfar A, Ghahremani S. A review of coronavirus disease (COVID-19) in children. J Ped Nephrol. 2020; 8 (03) 1-6
  • 6 Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020; 109 (06) 1088-1095
  • 7 Mao L, Jin H, Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020; 77 (06) 683-690
  • 8 Schober ME, Pavia AT, Bohnsack JF. Neurologic manifestations of COVID-19 in children: emerging pathophysiologic insights. Pediatr Crit Care Med 2021; 22 (07) 655-661
  • 9 Yasuhara J, Kuno T, Takagi H, Sumitomo N. Clinical characteristics of COVID-19 in children: a systematic review. Pediatr Pulmonol 2020; 55 (10) 2565-2575
  • 10 Badal S, Thapa Bajgain K, Badal S, Thapa R, Bajgain BB, Santana MJ. Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: a systematic review and meta-analysis. J Clin Virol 2021; 135: 104715
  • 11 Bhuiyan MU, Stiboy E, Hassan MZ. et al. Epidemiology of COVID-19 infection in young children under five years: a systematic review and meta-analysis. Vaccine 2021; 39 (04) 667-677
  • 12 Peluso L, Abella BS, Ferrer R, Kucher N, Sunde K, Taccone FS. Fever management in COVID-19 patients. Minerva Anestesiol 2021; 87 (01) 1-3
  • 13 Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?. Front Physiol 2021; 11: 571416
  • 14 El-Radhi AS. Fever in Common Infectious Diseases. Clinical Manual of Fever in Children 2019; 85-140
  • 15 Berger JR. COVID-19 and the nervous system. J Neurovirol 2020; 26 (02) 143-148
  • 16 Dewiyanti L, Sumarni N, Lie JD. et al. Children with COVID-19 who manifest febrile seizure. Case Rep Med 2021; 2021: 9992073
  • 17 Paniz-Mondolfi A, Bryce C, Grimes Z. et al. Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). J Med Virol 2020; 92 (07) 699-702
  • 18 Sweid A, Hammoud B, Bekelis K. et al. Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019. Int J Stroke 2020; 15 (07) 733-742
  • 19 Ye M, Ren Y, Lv T. Encephalitis as a clinical manifestation of COVID-19. Brain Behav Immun 2020; 88: 945-946
  • 20 Liu K, Pan M, Xiao Z, Xu X. Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019-2020. J Neurol Neurosurg Psychiatry 2020; 91 (06) 669-670
  • 21 Panda PK, Sharawat IK, Panda P, Natarajan V, Bhakat R, Dawman L. Neurological complications of SARS-CoV-2 infection in children: a systematic review and meta-analysis. J Trop Pediatr 2021; 67 (03) fmaa070
  • 22 Correia AO, Feitosa PWG, Moreira JLS, Nogueira SÁR, Fonseca RB, Nobre MEP. Neurological manifestations of COVID-19 and other coronaviruses: a systematic review. Neurol Psychiatry Brain Res 2020; 37: 27-32
  • 23 Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 2020; 323 (23) 2427-2429
  • 24 Bobker SM, Robbins MS. COVID-19 and headache: a primer for trainees. Headache 2020; 60 (08) 1806-1811
  • 25 Lin JE, Asfour A, Sewell TB. et al. Neurological issues in children with COVID-19. Neurosci Lett 2021; 743: 135567
  • 26 Aarli JA. The immune system and the nervous system. J Neurol 1983; 229 (03) 137-154
  • 27 McAlpine LS, Fesharaki-Zadeh A, Spudich S. Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?. Curr Opin Psychiatry 2021; 34 (02) 177-185
  • 28 Varatharaj A, Thomas N, Ellul MA. et al; CoroNerve Study Group. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry 2020; 7 (10) 875-882
  • 29 Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg 2020; 194: 105921
  • 30 Ray STJ, Abdel-Mannan O, Sa M. et al; CoroNerve study group. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health 2021; 5 (09) 631-641
  • 31 Patel NA. Pediatric COVID-19: systematic review of the literature. Am J Otolaryngol 2020; 41 (05) 102573
  • 32 McAbee GN, Brosgol Y, Pavlakis S, Agha R, Gaffoor M. Encephalitis associated with COVID-19 infection in an 11-year-old child. Pediatr Neurol 2020; 109: 94